![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
https://orcid.org/0000-0001-9388-3882
References
- Azziz R. 2018. Polycystic ovary syndrome. Obstetrics and Gynecology 132:321–336.
- Azziz R, Dumesic DA, Goodarzi MO. 2011. Polycystic ovary syndrome: an ancient disorder? Fertility and Sterility 95:1544–1548.
- Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. 2016. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction (Oxford, England) 31:2841–2855.
- Burk RF, Hill KE. 2005. Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis. Annual Review of Nutrition 25:215–235.
- Burk RF, Hill KE, Motley AK. 2001. Plasma selenium in specific and non-specific forms. BioFactors (Oxford, England) 14:107–114.
- Chen M, Liu B, Wilkinson D, Hutchison AT, Thompson CH, Wittert GA, Heilbronn LK. 2016. Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance. Obesity Research & Clinical Practice. https://doi.org/http://dx.doi.org/10.1016/j.orcp.2016.07.004
- Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. 2011. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Reviews. Endocrinology 7:219–231.
- Ibáñez L, Ong KK, López-Bermejo A, Dunger DB, de Zegher F. 2014. Hyperinsulinaemic androgen excess in adolescent girls. Nature Reviews. Endocrinology 10:499–508.
- Mani H, Levy MJ, Davies MJ, Morris DH, Gray LJ, Bankart J, et al. 2013. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clinical Endocrinology 78:926–934.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, et al. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man . Diabetologia 28:412–419.
- Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S, et al. 2010. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metabolism 12:483–495.
- Mita Y, Nakayama K, Inari S, Nishito Y, Yoshioka Y, Sakai N, et al. 2017. Selenoprotein P-neutralizing antibodies improve insulin secretion and glucose sensitivity in type 2 diabetes mouse models. Nature Communications 8:1658.
- Mohri K, Misu H, Takayama H, Ishii K-A, Kikuchi A, Lan F, et al. 2019. Circulating concentrations of insulin resistance-associated hepatokines, selenoprotein P and leukocyte cell-derived chemotaxin 2, during an oral glucose tolerance test in humans . Biol Pharm Bull 42:373–378.
- Oo SM, Misu H, Saito Y, Tanaka M, Kato S, Kita Y, et al. 2018. Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population. Scientific Reports 8:16727.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 19:41–47.
- Saito Y. 2020. Selenoprotein P as an in vivo redox regulator: disorders related to its deficiency and excess. Journal of Clinical Biochemistry and Nutrition 66:1–7.
- Saito Y, Takahashi K. 2000. Selenoprotein P: its structure and functions. Journal of Health Science 46:409–413.
- Saito Y, Takahashi K. 2002. Characterization of selenoprotein P as a selenium supply protein. European Journal of Biochemistry 269:5746–5751.
- Schomburg L, Schweizer U, Holtmann B, Flohé L, Sendtner M, Köhrle J, et al. 2003. Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues. The Biochemical Journal 370:397–402.
- Shetty SP, Shah R, Copeland PR. 2014. Regulation of selenocysteinein corporation into the selenium transport protein, selenoprotein P. Journal of Biological Chemistry 289:25317–25326.
- Takayama H, Misu H, Iwama H, Chikamoto K, Saito Y, Murao K, et al. 2014. Metformin suppresses expression of the selenoprotein P gene via an AMP-activated kinase (AMPK)/FoxO3a pathway in H4IIEC3 hepatocytes. The Journal of Biological Chemistry 289:335–345.
- Wang D-S, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y, et al. 2002. Involvement of organiccation transporter 1 in hepatic and intestinal distribution of metformin. Journal of Pharmacology and Experimental Therapeutics 302:510–515.
- Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, et al. 2011. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. Journal of Clinical Endocrinology and Metabolism. 96:E1325–E13259.